In this study 20 metallocene-based compounds comprising extensive structural diversity were synthesized and evaluated as carbonic anhydrase (CA, EC 4.2.1.1) inhibitors. These compounds proved moderate to good CA inhibitors in vitro, with several compounds displaying selectivity for cancer-associated isozymes CA IX and CA XII compared to offtarget CA I and CA II. Compound 6 was the most potent ferrocene-based inhibitor with K i s of 5.9 and 6.8 nM at CA IX and XII, respectively. A selection of key drug-like parameters comprising Log P, Log D, solubility, and in vitro metabolic stability and permeability were measured for two of the ferrocene-based compounds, regioisomers 1 and 5. Compounds 1 and 5 were found to have characteristics consistent with lipophilic compounds, however our findings show that the lipophilicity of the ferrocene moiety is not well modelled by replacement with either a naphthyl or a phenyl moiety in software prediction tools.
Introduction
Reports of safe and efficacious organometallic inhibitors for a growing number of therapeutically relevant enzymes have resulted in widened acceptance of organometallic compounds as viable candidates for targetted therapeutic applications.
1 To date numerous classes of organometallic compounds have found application in medicinal chemistry; these include metallocenes, half-sandwich metallocenes, metal carbenes, metal carbonyls and metalarene compounds. 1 The classical metallocenes, ferrocene and ruthenocene, are sandwich compounds wherein the metal is located between two cyclopentadienyl (Cp) rings. These compounds are stable in air, kinetically inert and uncharged, with their metal atom in a low oxidation state. Both ferrocene and ruthenocene are amenable to derivatization reactions such as Friedel-Craft acylations, formylation, sulfonation and lithiation (to name a few) and this permits a straightforward synthesis of metallocene-based organometallic compounds. 2 The toxicology of ferrocene is particularly well studied and this compound may be administered orally without toxicity. 3 Ferrocene is metabolized in the liver by cytochrome P450 enzymes similarly to benzenes. 3 Ferrocenium salts were the first organometallic compounds for which antiproliferative properties were reported 4 and today there are a number of ferrocene-based compounds that have found use as therapies. 3 Notably, the replacement of a benzene ring with a ferrocene fragment within the structure of two established drugs has led to compounds wherein the ferrocene chemistry is implicated in the drug mode of action. Hydroxyferrocifen is a ferrocene analogue of tamoxifen that selectively targets breast cancer 5 while ferroquine is a ferrocene analogue of chloroquine that targets the malaria parasite, both of these ferrocene analogues are in clinical development. 6 An alternate approach, wherein the ferrocene moiety is appended as a substituent onto a known pharmacophore, has been applied in a number successful medicinal chemistry campaigns to take advantage of the physicochemical and structural properties of ferrocene for improved biological activity. 3 Ruthenocene and its derivatives are much less studied than their isostructural ferrocenyl counterparts, and to date only a small number of ruthenocene-based compounds appear in the literature in the context of drug discovery.
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Carbonic anhydrases (CAs) are zinc metalloenzymes that catalyze the reversible hydration of carbon dioxide to bicarbonate and a proton. 8 CA isozymes IX and XII are overexpressed in cancer cells of many hypoxic tumors where they provide a pH-regulating system that contributes to hypoxic tumor cell survival and proliferation. 9 The significance of CAs role in cancer has triggered a need to develop novel, drug-like small molecule CA inhibitors as chemical tools and/or as leads for therapeutic drug discovery. 10 Small molecule CA inhibitors have recently been reported that show promising anticancer properties. 11 In this manuscript we report the design, synthesis, biological activity and selected ADME properties for a library of novel metallocene-based CA inhibitors. The development of metallocene-based compounds that can selectively kill tumor cells by inhibiting the validated oncology target CA IX, is a new approach with potential to deliver organometallic, drug-like compounds as future therapies. We recently reported the protein X-ray crystal structures of four of these compounds in complex with CA II (PDB accession codes 3P55, 3P3H, 3P44 and 3P3J), 12 while others have recently reported structures of piano-stool complexes bound to CA II. 13 Our study is the first wherein isomeric ruthenocene and ferrocene inhibitors have been complexed with the target protein and a crystal structure obtained. 12 The replacement of ferrocene (iron) with ruthenocene (ruthenium) altered the CA enzyme inhibition of these compounds in a manner consistent with the subtle but significant difference in structure provided by changing the metal. We demonstrated that although the metallocene moiety behaves chemically like an aromatic moiety such as a phenyl group, 7a the barrel-shaped sandwich structure of the metallocene fragment permits access to 3D structural permutations that are not possible with a flat aromatic ring. 12 We identified several hydrophobic interactions with the hydrophobic face of the CA II binding cavity and hypothesized that this may provide an avenue to continue to develop new metallocene-based compounds that better occupy the hydrophobic binding pocket of CAs active site to further inform structure-activity relationships (SAR) of this organometallic class of CA inhibitors.
Results and Discussion
Inhibitor design. The 'tail approach' has been applied to the design and synthesis of a growing number of potent and isozyme selective CA inhibitors. The approach involves covalently tethering a tail fragment onto the established primary sulfonamide CA recognition pharmacophore (R-SO 2 NH 2 where R = aromatic) to generate the extended pharmacophore:
[tail]-[aromatic]- [ZBG] . 14 The approach has provided a framework in which CA inhibitor properties can be readily tuned with respect to structure-property and structure-activity parameters to deliver CA inhibitors with biopharmaceutical characteristics that are appropriate for in vivo use. Commonly used covalent attachments between the aromatic group and tail fragment are ester, amide, imine, urea and thiourea linkers. Previous work in our research group has focussed on the 1,3-dipolar cycloaddition reaction (1, (17) (18) and urea (19) (20) linkers, Figure 2 . These linkers impart differing stability and hydrogen bonding attributes to these organometallic CA inhibitors.
Compounds 1-20 comprise two isomeric series, the first series is the para-substituted benzene (5-8, 12-14, 16 ). In addition to metallocenes 1-20, six additional analogues were synthesized wherein the triazole-metallocene tail fragment was replaced with either a triazole-phenyl tail fragment (21) (22) (23) (24) or an unsubstituted triazole fragment (25-26), Figure 3 . Compounds 21-26 were designed as controls to allow delineation of the metallocene contribution to SAR and structure-property relationships (SPR). is greater than for off-target isozymes I and II, a sought after selectivity profile with CA inhibitor development. Esters 9 and 12 are bioisosteres of amides 15 and 16, yet the esters remarkably exhibit two orders of magnitude better CA I and II inhibition than their corresponding amides. The para-substituted compound 9 (ester) and 15 (amide) have similar potency at CA IX and XII, while the meta-substituted compound 12 (ester) was a better CA IX and XII inhibitor than its amide counterpart 16. Increasing the length of the alkyl chain of the ester linkage (compare 9-11 and 12-14) had minimal effect on CA inhibition with the exception of the longer chain compound 11 which was a 10-fold better CA IX inhibitor (K i = 7.9 nM) than the shorter chain ester 9 and 10.
(iii) Para-substitution and meta-substitution. The ten para-substituted analogues (1-4, 9-11, 15, 17, 19) had CA I inhibition constants that ranged from 9-3900 nM, while the ten meta- In vitro ADME properties. The metallocene-based compounds in this study are good CA inhibitors in vitro, and in addition several compounds display selectivity for the cancerassociated CAs compared to off-target CAs. The design of useful drugs and/or probes for medicinal chemistry requires balancing compound activity with a number of different compound properties, with the knowledge that each impacts on the drugs performance in vivo.
A recent analysis of compounds published in the medicinal chemistry literature demonstrated that there is a noticeable creep of compound properties outside recognized drug-like parameters, 19 and here we were keen to build an understanding of the impact of the ferrocene moiety on a selection of key drug-like parameters. We have experimentally measured and determined Log P, Log D, solubility, metabolism and in vitro permeability for four CA inhibitors sharing the core structure of a disubstituted triazole benzenesulfonamide: two ferrocene-based compounds (regioisomers 1 and 5), and two analogues of 1, one where the ferrocene is replaced by a phenyl moiety (compound 21), and another where the ferrocene is replaced by a glucosyl moiety (compound 37), Figure 5 . Compounds for ADME studies.
Lipophilicity. Log P and Log D describe a compound's lipophilicity, and values often correlate with a number of key biopharmaceutical parameters in drug discovery. Table 2 shows experimental Log P and Log D values for compounds 1, 5, 21 and 37 and calculated Log P (cLog P) values for compounds 21, 37 and 38. The Log D (Log D at pH 7.4 and pH 3.0) values were measured using both a RP-HPLC method 20 and the traditional shake flask method. As expected from the ionization properties of the compounds (expected to be neutral at both pH values), pH did not impact on the measured partition coefficients, Table 2 . Ferrocene-based regioisomers 1 and 5 had similar Log D 7.4 and Log D 3.0 values, with values ~0.6 log units higher than for the phenyl compound 21. This demonstrates that the ferrocene moiety is more strongly lipophilic than the phenyl moiety. As expected, carbohydrate-based compound (37) with four hydroxyl groups has a markedly reduced Log D value (Log D 7.4 or 3.0 of -0.1) compared to compounds 1, 5 and 21, this is consistent with the increased hydrophilicity of 37.
The use of software tools to predict Log P (cLog P) is now routine in medicinal chemistry, however common programs lack a metallocene substructure in their training set.
The experimentally measured octanol-water partition coefficient for ferrocene is 3.46. 21 This was of the same order as that measured for naphthalene (3.30) , but much higher than that for benzene (2.13). 21 Using ChemDraw Ultra 12 software the cLog P for the virtual compound 38, where a naphthyl moiety replaces the ferrocenyl moiety of 1, is 3.7. This value is 0.8 log units higher than the experimentally determined Log D 7.4 value for 1 and 5. The cLog P for the phenyl compound 21 is 2.5 (close to the measured value) and is 0.4 log units lower than the experimentally determined Log D 7.4 value for 1 and 5. The ferrocene moiety lipophilicity of compounds 1 and 5 is thus not well modelled by replacement with either a naphthyl or a phenyl moiety as the measured LogD of ferrocene-based compounds 1 and 5 falls between the clog P values calculated for these two aromatics. Table 2 . For all compounds tested, there was good mass balance (>80%)
indicating minimal retention of compounds within the cell monolayer and minimal non- Solubility. Solubility is another property that can significantly affect oral absorption of a drug.
The kinetic and equilibrium solubility results for the four test compounds (at pH 2.0, pH 6.5
and in water) are presented in Table 4 . The kinetic solubility results (presented as a range) exhibited a similar trend to the equilibrium solubility results, although the absolute values differ. The glycoconjugate CA inhibitor 37 has moderate kinetic solubility and good equilibrium solubility, suggesting that the kinetic solubility assay underestimates the actual solubility of this compound. Metallocene compound 1 and phenyl compound 21 were found to be sparingly soluble under both kinetic and equilibrium conditions. Interestingly metallocene compound 5, the regioisomer of compound 1, has moderate solubility, with values reasonably consistent under both kinetic and equilibrium conditions. There was no apparent degradation of the compounds in microsomal matrix in the absence of cofactors, suggesting that the apparent rates of degradation in the presence of cofactor were due solely to cofactor-dependent microsomal metabolism. There was also no major increase in the rate of degradation observed in microsomal samples containing NADPH and UDPGA (supplemented with the pore-forming peptide, alamethicin) relative to NADPH alone, suggesting that these compounds were not susceptible to primary glucuronidation in the microsomal test system, Table 5 . 
Conclusions
In n-hexane then 100 % ethyl acetate) using solid addition from ethyl acetate. 
General

3-(4-Ferrocenyl-1H-1,2,3-triazol-1-yl)benzenesulfonamide (5).
3-(5-Ferrocenyl-1H-1,2,3-triazol-1-yl)benzenesulfonamide (6).
2-(1-(3-Sulfamoylphenyl)-1H-1,2,3-triazol-4-yl)ethyl ferrocenyl-1-carboxylate (13
Prop-2-ynyl ferrocenyl-1-carboxamide (32)
The title compound was prepared from propargyl amine according to a modified General Procedure 3 (omit -4-dimethylamino pyridine, THF as solvent, purification by silica gel chromatography (1:9 methanol:dichloromethane)) and isolated as an orange solid (281 mg, 
3-Azidobenzenesulfonamide (34).
To a suspension of 3-aminobenzenesulfonamide (5.0 g, 29 mmol, 1.0 equiv.) in acetonitrile (50 mL) at 0 ºC was added dropwise t-butyl nitrite (5.0 mL, 1.5 equiv.), followed by azidotrimethylsilane (3.4 mL, 1.2 equiv.). The resulting bright yellow solution was stirred at rt for 16 h. The reaction mixture was reduced to dryness in vacuo and the remaining residue dissolved in EtOAc (50 mL) and washed with brine (50 mL). The aqueous phase was back-extracted with EtOAc (50 mL), the organic fractions were combined and again washed with brine (2 × 50 mL), dried (MgSO 4 ) and the solvent volume reduced (ca.
20 mL). The product was precipitated by addition of n-hexane, collected by vacuum filtration and washed with n-hexane to produce a pale yellow solid (3.7 g, 19 mmol, 64% Solubility Measurements. The solubility in aqueous buffers was determined using either a kinetic screening method or an equilibrium method. For the kinetic method, compound in DMSO (10 mg/mL) was spiked into either pH 6.5 phosphate buffer or 0.01 M HCl (approximate pH 2.0) with the final DMSO concentration being 1%. Samples were then analysed via nephelometry to determine a solubility range. 22 Equilibrium solubility measurements were conducted by adding media (water, pH 2 or pH 6.5 buffers) to pre-weighed compound in screw cap polypropylene tubes, followed by vortexing and incubating at 25 °C for 24 h. Additional compound was added if compounds were completely dissolved to ensure that the solution was saturated. Sampling was performed after 1, 4 and 24 h by centrifuging (3 min x 10, 000 rpm) and then removing aliquots of the supernatant for analysis by LCMS.
In Vitro Metabolic Stability. Human liver microsomes (BD Gentest, Discovery Labware Inc., Woburn, Massachusetts) were suspended in 0.1 M phosphate buffer (pH 7.4) at a final protein concentration of 0.4 mg/mL and incubated with compounds (1 µM) at 37 °C. An NADPHregenerating system (1 mg/mL NADP, 1 mg/mL glucose-6-phosphate, 1 U/mL glucose-6-phosphate dehydrogenase) and MgCl 2 (0.67 mg/mL) was added to initiate the metabolic reactions, which were subsequently quenched with ice-cold acetonitrile at time points ranging from 0 -60 min. Samples were also incubated in the absence of co-factor to monitor for noncytochrome P450-mediated metabolism in the microsomal matrix. Samples were then centrifuged and the concentration of parent compound remaining in the supernatant monitored by LCMS. The first order rate constant for substrate depletion was determined by fitting the data to an exponential decay function and these values were used to calculate the in vitro intrinsic clearance (CL int ) and the predicted in vivo intrinsic clearance value (CL int vivo ) as previously described. 23 The predicted in vivo hepatic extraction ratio (E h ) was calculated using the following relationship: E h = CL int vivo / (Q + CL int vivo ) where Q is liver blood flow (20.7 mL/min/kg).
LCMS Analysis. LCMS analysis was conducted using a Waters Acquity HPLC system coupled to either a Waters Xevo or a Waters Quattro Ultima Primier mass spectrometer operated under positive ion MS-MS conditions. The column was a Supelco Ascentis Express Amide (2.7 µm, 50 x 2.1 mm i.d.) maintained at a column temperature of 40 °C. HPLC analysis was performed using a mobile phase consisting of water and methanol containing 0.005% ammonium formate at a flow rate of 0.4 mL/min and separation was achieved under gradient conditions varying the methanol content from 2 to 95 % followed by requilibration to the starting conditions. Processed samples were maintained in the autosampler at a temperature of 10 °C and 5 µL were injected onto the column. The conditions described led to the elution of 35, 21, 1, and 5 after 1.84, 2.22, 2.41 and 2.41 min respectively. Compounds were quantified by comparison to calibration curves prepared in the sample matrix.
